Antibody modulation: Limiting the efficacy of therapeutic antibodies

by Vaughan, Andrew T., Cragg, Mark, Beers, Stephen A.
Published 2015

The antibacterial properties of secreted phospholipases A(2) - A major physiological role for the group IIA enzyme that depends on the very high pI of the enzyme to allow penetrati...

by Beers, S.A, Buckland, A.G, Koduri, R.S, Cho, W., Gelb, M.H, Wilton, D.C
Published 2001

Inhibitory FcyRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity

by Vaughan, A.T, Iriyama, C., Beers, S.A, Chan, C.H.T, Lim, S.H, Williams, E.L, Shah, V., Roghanian, A., Frendeus, B., Glennie, M.J, Cragg, M.S
Published 2014

Immunotherapy targeting inhibitory Fc? receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization

by Williams, E.L, Tutt, A.L, Beers, S.A, French, R.R, Chan, C.H.T, Cox, K.L, Roghanian, A., Penfold, C.A, Butts, C.L, Boross, P., Verbeek, J.S, Cragg, M.S, Glennie, M.J
Published 2013

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

by Beers, Stephen A., French, Ruth R., Chan, Claude H.T, Lim, Sean H., Jarrett, Timothy C., Mora Vidal, Regina, Wijayaweera, Sahan S., Dixon, Sandra V., Kim, Hyung J., Cox, Kerry L., Kerr, Jonathan P., Johnston, David A., Johnson, Peter W.M, Verbeek, Sjef, Glennie, Martin J., Cragg, Mark S.
Published 2010

Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies

by White, Ann L., Chan, H.T. Claude, French, Ruth R., Willoughby, Jane E., Mockridge, C. Ian, Roghanian, Ali, Penfold, Christine A., Booth, Steven G., Dodhy, Ali, Polak, Marta E., Potter, Elizabeth A., Ardern-Jones, Michael R., Verbeek, J. Sjef, Johnson, Peter W.M, Al-Shamkhani, Aymen, Cragg, Mark S., Beers, Stephen A., Glennie, Martin J.
Published 2015

HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy

by Beers, S.A, Booth, S.G, Carter, M.J, Chee, S.J, Cleary, K.L.S, Cragg, M.S, Cutress, R.I, Dahal, L.N, Douglas, J., Foxall, R.B, French, R.R, Frendéus, B., Ghorbani, M., Glennie, M.J, Hargreaves, C.E, Hussain, K., James, S., Kemp, R.S, Liu, R., Longley, J., Macari, S., Markham, H., Müller, K.T.J, Murray, T., Oldham, R.J, Ottensmeier, C.H, Roghanian, A., Smith, R.C.G, Stopforth, R.J, Strefford, J.C, Thirdborough, S.M
Published 2022

HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy

by Beers, S.A, Booth, S.G, Carter, M.J, Chee, S.J, Cleary, K.L.S, Cragg, M.S, Cutress, R.I, Dahal, L.N, Douglas, J., Foxall, R.B, French, R.R, Frendéus, B., Ghorbani, M., Glennie, M.J, Hargreaves, C.E, Hussain, K., James, S., Kemp, R.S, Liu, R., Longley, J., Macari, S., Markham, H., Müller, K.T.J, Murray, T., Oldham, R.J, Ottensmeier, C.H, Roghanian, A., Smith, R.C.G, Stopforth, R.J, Strefford, J.C, Thirdborough, S.M
Published 2022

Antagonistic human FcyRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo

by Roghanian, Ali, Teige, Ingrid, Mårtensson, Linda, Cox, Kerry L., Kovacek, Mathilda, Ljungars, Anne, Mattson, Jenny, Sundberg, Annika, Vaughan, Andrew T., Shah, Vallari, Smyth, Neil R., Sheth, Bhavwanti, Chan, H.T. Claude, Li, Zhan-Chun, Williams, Emily L., Manfredi, Giusi, Oldham, Robert J., Mockridge, C. Ian, James, Sonya A., Dahal, Lekh N., Hussain, Khiyam, Nilsson, Björn, Verbeek, J. Sjef, Juliusson, Gunnar, Hansson, Markus, Jerkeman, Mats, Johnson, Peter W.M, Davies, Andrew, Beers, Stephen A., Glennie, Martin J., Frendéus, Björn, Cragg, Mark S.
Published 2015